RxDoctor Payments DataLook up a doctor →

Jose Gamez, MD

Psychiatry · Hialeah, FLNPI 1134210271

Payments from drug & device makers

$14,770,309in general payments, 2019–2025

Across 2,453 payments — averaging $6021.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$5.8M
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$1.7M
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1.3M
  • Eisai Inc.$891K
  • Hoffmann-la Roche Limited$769K
  • Janssen Research & Development, LLC$609K
  • plus $3.7M from 39 others
$5,491in research payments, 2019–2025

Across 28 payments — averaging $196.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
  • Acadia Pharmaceuticals Inc$2K
  • Lundbeck LLC$2K
  • Supernus Pharmaceuticals, Inc.$84

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.340$5,818,311
Otsuka Pharmaceutical Development & Commercialization, Inc.31$1,710,869
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)397$1,264,643
Eisai Inc.244$890,701
Hoffmann-la Roche Limited14$769,095
Janssen Research & Development, LLC66$609,069
AbbVie(2 entities)157$581,405
E.r. Squibb & Sons, L.L.C.52$519,959
Acadia Pharmaceuticals Inc254$324,384
Boehringer Ingelheim5$311,013
Neurocrine Biosciences, Inc.273$224,491
Boehringer Ingelheim International GmbH120$196,997
Eli Lilly3$195,985
Biohaven Pharmaceuticals, Inc.11$174,383
UCB SA9$158,748
Supernus Pharmaceuticals, Inc.23$148,548
Bristol Myers Squibb16$113,705
Livanova USA, Inc.70$104,868
Sumitomo Pharma America, Inc.15$103,934
F. Hoffmann-la Roche AG15$83,969
Grifols Biologicals LLC2$83,802
Otsuka America Pharmaceutical, Inc.131$76,093
Novo Nordisk AS38$63,294
Mallinckrodt LLC8$60,285
Avanir Pharmaceuticals, Inc.18$56,251
Sunovion Pharmaceuticals Inc.12$39,002
Genentech, Inc.2$35,768
Alkermes, Inc.24$22,076
Pfizer3$12,000
Biohaven Pharmaceutical Holding Company Ltd.1$8,171
Bioxcel Therapeutics, Inc.1$3,000
Boehringer Ingelheim RCV GmbH & Co KG28$2,734
Bausch Health US, LLC25$584
Johnson & Johnson5$546
Axsome Therapeutics, Inc.4$254
Jazz Pharmaceuticals Inc.2$244
Lundbeck LLC8$212
Corium, LLC4$178
Almatica Pharma LLC6$155
Vanda Pharmaceuticals Inc.6$134
Amgen1$115
Idorsia Pharmaceuticals US Inc2$109
Merck2$95
Alpha Cognition USA, Inc.3$86
Takeda Pharmaceuticals U.S.A., Inc.2$44

How this compares

$14,770,309 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida →

Medicare billing

Part B allowed, 2024
$265,516
Medicare patients
1,003
Services billed
2,930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other psychiatry in Hialeah

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →